

## **Irrimax** complaint

**Sydney, Australia Friday, 27 August 2021**, Next Science Limited (ASX:NXS) (**Next Science / Company**) advises that Irrimax Corporation has filed a complaint in the United States District Court for the Northern District of Georgia alleging common law unfair competition and false advertising regarding XPerience<sup>TM</sup>.

Next Science is a new entrant in the surgery irrigation market with XPerience<sup>TM</sup>, a FDA cleared no rinse antimicrobial solution. Next Science has independent third party data showing the performance of XPerience<sup>TM</sup> compared with other in-market surgery irrigation products. Irrimax Corporation is a supplier of a chlorhexidine wash (99.95% water 0.05% chlorhexidine) into the surgery irrigation market.

Next Science stands by the independently verified performance of XPerience™, strenuously denies the allegations and intends to vigorously defend the complaint if and when it is served on Next Science.

Approved and authorised for release by Next Science's Managing Director.

Further information:

## **Judith Mitchell**

Managing Director, Next Science Limited

Phone: +61 2 9375 7989

Email: investorqueries@nextscience.com

## **Michael Brown**

Pegasus Advisory

Phone: +61 400 248 080

Email: mbrown@pegasusadvisory.com.au

## **About Next Science**

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company's primary focus is on the development and continued commercialisation of its proprietary Xbio<sup>TM</sup> technology to reduce the impact of biofilm-based infections in human health. Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio technology. For further information visit: www.nextscience.com.